Tag: BioNTech

Following a period of significant pressure after its founders announced their departure, BioNTech is shifting investor focus back to its ...

The European Lung Cancer Congress in Copenhagen, which opens today, serves as a critical platform for BioNTech to showcase its ...

The investment narrative surrounding BioNTech is currently being shaped by a confluence of challenges. Despite the company's strategic moves to ...

The year 2026 is shaping up to be a decisive period for BioNTech as it seeks to solidify its transition ...

The future trajectory of BioNTech SE is becoming increasingly tied to a single, promising oncology asset. The company’s ambitious cancer ...

A significant strategic transition is underway at Mainz-based biotechnology firm BioNTech. While news of the impending departure of its two ...

The German biotech firm BioNTech is navigating its most significant transition since the peak of the pandemic. Co-founders Ugur Sahin ...

The German biotech firm BioNTech is navigating its most significant strategic transition to date. Two concurrent developments have unsettled the ...

The architects of Germany's celebrated vaccine breakthrough are stepping back from day-to-day leadership. BioNTech SE's co-founders, Uğur Şahin and Özlem ...

Today's release of BioNTech's full-year 2025 financials is drawing investor attention away from quarterly earnings and toward the company's evolving ...